StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Stock analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.

Lipocine Trading Down 3.7 %

Shares of LPCN stock opened at $4.45 on Friday. The firm has a fifty day simple moving average of $4.89 and a 200-day simple moving average of $5.04. The company has a market capitalization of $23.81 million, a PE ratio of -5.86 and a beta of 1.23. Lipocine has a twelve month low of $3.20 and a twelve month high of $11.79.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Equities research analysts predict that Lipocine will post -0.78 EPS for the current year.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC raised its stake in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the period. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.